In this consideration, besides anti-PD-1, other immune checkpoint inhibitors such as anti-BTLA, anti-CTLA-4, anti-Siglec-10, anti-TIGIT, anti-TIM-3, anti-LAG-3 could be tested in combination to investigate their suitability for enhancing Vδ2 T cell efficacy in this mesothelioma model. The gene discussed is BTLA; the disease is mesothelioma.